胶质瘤患者接受替莫唑胺同步放疗期间对耶氏肺孢子菌肺炎(PJP)预防的认知——患者与医生调查
该单中心患者调查与全国医生调查探讨胶质瘤患者接受替莫唑胺同步放疗(TMZ-RT)时PJP预防的作用。仅2.4%(1/41)患者接受预防,仅1例未预防者因肺炎住院;77%(17/22)医生认为预防证据弱,58%(11/19)不常规处方,73%(16/22)认为应限于有其他危险因素者。作者认为当前常规预防推荐需重新考虑。
要点
- 仅2.4%(1/41)患者接受PJP预防,1例未预防者因肺炎住院。
- 77%(17/22)医生认为PJP预防证据弱,58%(11/19)不常规处方。
- 73%(16/22)医生认为预防应限于有其他危险因素的患者。
核心结论
- 作者认为,在当前推荐下对无其他危险因素的TMZ-RT患者常规处方PJP预防值得重新考虑。
研究设计与样本
- 单中心患者调查与全国医生调查,探讨胶质瘤患者接受TMZ-RT时PJP预防的作用。
主要发现
- 23%(31/133)医生和60%(44/73)患者完成调查;患者中位年龄42岁(范围20-77),85%(34/40)完成辅助TMZ。
- 仅2.4%(1/41)患者接受PJP预防,仅1例未接受预防者因肺炎住院。
- 在假设PJP风险下,13.2%(5/38)患者担心PJP感染,26%(10/38)担心预防性抗生素潜在副作用。
- 77%(17/22)医生认为PJP预防证据弱,58%(11/19)不常规处方预防,73%(16/22)认为预防应限于有其他危险因素的患者。
- 超过95%医生估计过去5年执业中PJP发生率<1%(无论是否预防);73%(16/22)医生处方预防需PJP感染风险达3-8%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pneumocystis jirovecii pneumonia (PJP) prophylaxis is required by provincial and national drug monographs during glioma treatment using temozolomide (TMZ) concurrently with radiation (TMZ-RT). However, real-world data suggest the potential benefits of PJP prophylaxis may not outweigh its potential harms in this population. METHODS: We conducted a single-center patient survey and a national physician survey to explore the role of PJP prophylaxis amongst glioma patients undergoing TMZ-RT. RESULTS: 23% (31/133) of physicians and 60% (44/73) of patients completed a survey. The median patient age was 42 (range 20-77); 85% (34/40) had completed adjuvant TMZ. Although only 2.4% (1/41) of patients received PJP prophylaxis, only one person (without PJP prophylaxis) was hospitalized for pneumonia. When presented with hypothetical PJP risks, 13.2% (5/38) of patients were concerned about PJP infection, while 26% (10/38) were concerned about potential side effects from prophylactic antibiotics. Most physicians (77%, 17/22) perceived the evidence for PJP prophylaxis as weak; 58% (11/19) did not routinely prescribe prophylaxis, and 73% (16/22) felt that PJP prophylaxis should be limited to patients with additional risk factors. Over 95% of physicians estimated that the incidence of PJP was < 1% in their last 5 years of practice regardless of PJP prophylaxis. For 73% (16/22) of physicians, to prescribe PJP prophylaxis, the risk of PJP infection needed to be 3-8%. CONCLUSION: The current recommendation to routinely prescribe PJP prophylaxis in patients receiving TMZ-RT in the absence of other risk factors warrants reconsideration.
引用
- Beltran-Bless AA, Alshamsan B, Jia J, et al. Perception of pneumocystis jirovecii pneumonia (PJP) prophylaxis in glioma patients receiving concurrent temozolomide and radiation- a patient and physician survey. J Neurooncol. 2024. PMID: 39105955. doi:10.1007/s11060-024-04764-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。